18.25 +0.20 (1.11%)
Pre-Market: 8:25AM EDT
|Bid||18.30 x 800|
|Ask||18.35 x 800|
|Day's Range||17.00 - 18.85|
|52 Week Range||8.00 - 27.50|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.20|
Kensho genetic engineering index has jumped 45% in the past year. It's top components, Uniqure NV, Sangamo Therapeutics and Abeona Therapeutics.
There are markets that are primarily driven by the indices and there are markets that are primarily driven by individual stocks. This is the latter. The DJIA is trading close to flat but there is some exceptionally strong action in individual stocks.
NEW YORK, June 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Accenture ...
NEW YORK, NY / ACCESSWIRE / June 12, 2018 / U.S. markets inched higher Monday as investors await details from the upcoming summit between President Donald Trump and North Korean leader Kim Jong Un in Singapore. ...
This Wednesday, WallStEquities.com has initiated reports coverage on the following Biotechnology equities: Riot Blockchain Inc. (NASDAQ: RIOT), RXi Pharmaceuticals Corp. (NASDAQ: RXII), Sage Therapeutics Inc. (NASDAQ: SAGE), and Sangamo Therapeutics Inc. (NASDAQ: SGMO).All you have to do is sign up today for this free limited time offer by clicking the link below. Castle Rock, Colorado-based Riot Blockchain Inc.'s stock finished Tuesday's session 0.91% higher at $7.80 with a total trading volume of 296,284 shares.
Quite often in stock markets, companies that offer something novel and unique attract speculators. CRSP stock has two positive catalysts at this time. Fundamentally, the company’s high valuation could limit any more near-term upside, though.
RICHMOND, Calif., June 4, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom has granted ...
NEW YORK, NY / ACCESSWIRE / May 31, 2018 / U.S. equities rebounded on Wednesday, lifted by strong performance from the energy sector and worries over Italy's political crisis eased. The Dow Jones Industrial ...
RICHMOND, Calif. , May 30, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that management will present a corporate overview at the 2018 Jefferies Global Healthcare Conference ...
In December 2017, CRISPR Therapeutics (CRSP) entered a collaboration with Vertex Pharmaceuticals (VRTX) for the co-development and co-commercialization of CTX001. CRISPR Therapeutics submitted a CTA (clinical trial application) for CTX001 for the initiation of phase 1/2 trial for the evaluation of the safety and efficacy in the treatment of beta-thalassemia in Europe. CRISPR Therapeutics plans to submit an Investigational New Drug application to the FDA for the approval of an initiation of phase 1/2 clinical trial in the US for the treatment of sickle cell disease in the second half of 2018.
After decades of research into gene editing, this biotech company could be on the cusp of developing game-changing new treatments for rare diseases.
Bioverativ Inc., a Sanofi company dedicated to transforming the lives of people with rare blood disorders, and Sangamo Therapeutics, Inc. (SGMO) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Investigational New Drug (IND) application for BIVV003, a gene-edited cell therapy candidate for the treatment of people with sickle cell disease. Bioverativ and Sangamo are developing BIVV003 as part of an exclusive worldwide collaboration to develop and commercialize gene-edited cell therapies for sickle cell disease and beta thalassemia.
On a per-share basis, the Richmond, California-based company said it had a loss of 23 cents. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
Conference Call and Webcast Scheduled for 8:00 a.m. Eastern Time Today RICHMOND, Calif. , May 8, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today reported first quarter 2018 financial ...
"Curt has executed a series of significant pharmaceutical collaborations that have brought renewed validation to Sangamo's innovative research and technology platform and has provided me valuable counsel on corporate strategy," said Sandy Macrae, CEO of Sangamo. "We now have a strong balance sheet which enables us to pursue our strategy to retain ownership of our own products for development and potential commercialization in our chosen therapeutic areas. Herberts, 37, joined Sangamo in 2010 as Director of Corporate Development.
RICHMOND, Calif. , May 1, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) announced today that the company will release its first quarter 2018 financial results before the market opens on ...
RICHMOND, Calif. , May 1, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) today announced that data from the Company's technology and preclinical research programs will be presented at the ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on April 30) CareDx Inc (NASDAQ: CDNA ) Eleven Biotherapeutics Inc (NASDAQ: ...
RICHMOND, Calif., April 30, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced the completion of its previously announced underwritten public offering of 14,156,500 shares of its common stock at a price to the public of $16.25 per share, including 1,846,500 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. All of the shares were sold by Sangamo. Including the option exercise, the aggregate gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $230.0 million.
RICHMOND, Calif., April 27, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) announced today that the California Institute for Regenerative Medicine (CIRM) has awarded an $8 million grant for Sangamo to evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. "CIRM plays a critical role in funding the rigorous evaluation of new stem cell therapies, and we are very pleased to receive CIRM's support for the study of ST-400 for the treatment of transfusion-dependent beta-thalassemia," said Edward Conner, M.D., chief medical officer at Sangamo.
RICHMOND, Calif., April 25, 2018 /PRNewswire/ -- Sangamo Therapeutics, Inc. (SGMO) today announced the pricing of an underwritten public offering of 12,310,000 shares of its common stock at a price to the public of $16.25 per share. All of the shares are being sold by Sangamo. The gross proceeds to Sangamo from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be approximately $200.0 million.